Trial Profile
Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 03 May 2023 Planned End Date changed from 30 Aug 2022 to 15 Aug 2024.
- 03 May 2023 Planned primary completion date changed from 30 Aug 2022 to 15 Aug 2023.
- 01 Sep 2021 Planned End Date changed from 6 Sep 2021 to 30 Aug 2022.